The visualization of abnormal parathyroid glands is difficult due to their variations in number and localization. Noninvasive parathyroid imaging studies include 99mTc-sestamibi scintigraphy, ultrasonography, computed tomography scanning, magnetic resonance imaging, and positron emission tomography. There is a general consensus that the most sensitive and specific imaging modality, especially when it is combined with single-photon emission CT is the scintigraphy with 99mTc-sestamibi or 99mTc-tetrofosmin. 99mTc-sestamibi scintigraphy significantly increases the role of preoperative scintigraphy in patients with hyperparathyroidism and allows unilateral surgical approach with minimally invasive parathyroidectomy to be used. Generally, three protocols with the use of two radiopharmaceuticals, 99mTc-sestamibi or 99mTc-tetrofosmin, are most widely applied: single-phase dual-isotope subtraction, dual-phase single-isotope and combination of both. Each one of them has specific advantages and disadvantages. While single parathyroid adenomas are localized with greater precision, hyperfunctioning parathyroid hyperplastic cells represent a real challenge to the imaging modalities. Several factors can influence the radionuclide uptake in pathologically changed parathyroid cells, like the size, the level of their functional activity, the quantity of oxyphilic cells, mitochondria, P glycoprotein and other MDR gene products.
- parthyroid scintigraphy
- 99mTc pertechnetate
Noninvasive parathyroid imaging studies include technetium (99mTc) sestamibi scintigraphy, ultrasonography (US), computed tomography (CT) scanning, magnetic resonance imaging (MRI) and positron emission tomography (PET). Parathyroid glands need to be examined in case of a diagnosed hyperparathyroidism as a part of preoperative localization of the abnormal glands. Hyperparathyroidism is characterized by elevated parathyroid hormone (PTH) levels in the blood. Due to the underlying cause, it can be divided into primary and secondary. The primary hyperparathyroidism (PHPT) is due to excessive production of PTH from one or more abnormal parathyroid glands. Secondary hyperparathyroidism (SHPT) is a result of hypocalcemia caused by other concomitant diseases (end stage kidney renal disease, etc.). In SHPT usually more than one parathyroid glands are affected. Considered rare disease in the past, the incidence of PHPT has changed dramatically during the last 30 years with the introduction of routine calcium measurements in clinical practice, and is now considered to be approximately 42 per 100,000 persons. Women are affected more frequently than men, in a ratio of approximately 3:1. PHPT occurs predominantly in individuals in their middle years with a peak incidence between ages 50 and 60 years and can reach 4 cases per 1000 persons in women after their 60s. At the time of diagnosis, most patients with PHPT do not have classic symptoms like osteitis fibrosa cystica, nephrocalcinosis, nephrolithiasis or other signs associated with the disease. Symptomatic PHPT is now exception rather than the rule, with more than three-fourths of patients having no symptoms making detected changes of the blood values of calcium, phosphorus and parathyroid hormone (PTH) to be the only reason for diagnosis [1, 2]. By far, the most common lesion found in patients with PHPT is the solitary parathyroid adenoma, occurring in 85–90% of patients, while in the rest 10–15% primary hyperplasia of the parathyroid glands is present . In the past the standard surgical approach for PHPT was the bilateral four-gland parathyroid exploration with the removal of each gland which showed changes macroscopically. While in most of the patients with PHPT only one parathyroid gland is being affected, the above mentioned surgical approach is inappropriate in all cases. Unilateral approaches are appealing in a disease in which only a single gland is involved. So nowadays, the currently most widely used surgical approach is the minimally invasive parathyroidectomy which is connected with less postsurgical complications and shortens the time of operation . To be successful this procedure needs to rely on a precise preoperative localization of the abnormal parathyroid glands. That is, why preoperative parathyroid imaging gained so large importance. The rationale for locating abnormal parathyroid glands prior to surgery is that they can be notoriously unpredictable in their location.
2. Anatomy of the parathyroid glands
Parathyroid glands differ in shape and size. Typically four glands are present and are located adjacent to the dorsal surface of the thyroid lobes-two upper and two lower pairs. Normal glands tend to be flat and oval and normal measurements are 3 × 5 × 7 mm . The combined weight of all parathyroid glans is 90–130 mg and the superior glands are smaller than the inferior [6, 7]. Autopsy series demonstrate that four glands are found in 91% in subjects, five glands in 4%, and three glands in 5% . Approximately 5% of humans have supernumerary (more than four) parathyroid glands . Supernumerary glands are most commonly found within the thymus. Although gland distribution may deviate widely, the superior parathyroid glands, originating from the fourth pharyngeal pouch, are commonly found along the posterior surface of the upper two-thirds of the thyroid gland (92%). The inferior parathyroid glands have a more variable distribution than the superior ones. They originate from the third pharyngeal pouch together with the thymus. They migrate caudally until they reach the lower pole of the thyroid gland and 17% of them touch the inferior border of the thyroid gland, 26% are within the superior horn of the thymus, and 2% are in the mediastinal thymus . The variable anatomic distribution makes the inferior glands more difficult to locate than the superior ones. Histologically parathyroid glands are made of chief, oxyphillic and transient oxyphillic cells mixed with fat tissue. Chief cells produce PTH. The oxyphillic cells which are rich of mitochondria are with poorly defined function .
3. Noninvasive parathyroid imaging
The normal parathyroid glands cannot be visualized. The lack of the perfect imaging method for precise localization of parathyroid adenomas had led to search for an alternative imaging techniques. Ultrasonography (US) is one of the most widely used procedures. Because of the great anatomic variations of the parathyroid glands, their small sizes, the presence of more than one abnormal gland and the higher frequency of concomitant morphological changes of the thyroid gland, US proved to be specific but with low sensitivity. The success of US is highly operator dependent . Rapid spiral thin-slice CT scanning of the neck and mediastinum with evaluation of axial, coronal and sagittal views can add much to the search for elusive parathyroid tissue . MRI can also identify abnormal parathyroid tissue, but it is time consuming and expensive. It is also less sensitive than other modalities. It can nonetheless be useful when the search with the other noninvasive approaches has been unsuccessful. PET/CT can be used, but like MRI, it is expensive and does not have the kind of experiential basis that make it attractive. There are limiting data for using PET/CT in parathyroid imaging. PET with 18F-fluorodeoxyglucose (18F-FDG) was used with varying success. One study showed that 18F-FDG РЕТ was more sensitive but less specific than 99mTc-sestamibi SPECT . Others reported very low sensitivity for detecting abnormal parathyroid glands . Using РЕТ with 11C-methionine in parathyroid examination has been studied in some patients but because of the very short half-life of 11C-methionine, only 20 min its use is limited only to nuclear medicine centers located near to a cyclotron. There is a general consensus that the most sensitive and specific imaging modality, especially when it is combined with single-photon emission CT (SPECT) is the scintigraphy with 99mTc-sestamibi or 99mTc-tetrofosmin.
4. Parathyrod scintigraphy
Historically, the success of scintigraphy had been compromised by the failure of finding a pharmaceutical agent with specific topic accumulation in parathyroid glands and their close proximity to the thyroid gland. That is why to find a reliable method to differentiate both glands on scintigraphy was crucial. This was first achieved by a combined use of two radionuclides with different uptake in the thyroid and parathyroid cells. The latter allowed to perform a subtraction of the obtained images of both glands and to visualize only the abnormal parathyroid gland, but this proved to be time consuming and with greate radiation exposure to the patients. The first widely used radionuclide for detecting hyperfunctioning parathyroid glands during the 80s was 201Thallium chloride (201Tl). 201Tl chloride accumulates equally in thyroid and parathyroid cells. To make differentiation possible, its application was followed by an injection of 99mTc pertechnetate, with predominant thyroid uptake. Then 99mTc pertechnetate thyroid images were digitally subtracted from the images obtained with 201Tl chloride to allow visualization only of the parathyroid glands .
Introduced in clinical practice by Coakley et al. , the 99mTc-sestamibi scintigraphy significantly increased the role of preoperative scintigraphy in patients with hyperparathyroidism. Firstly used as a cardiotropic agent this radionuclide showed increased accumulation in a variety of benign and malignant tumors. 99mTc-sestamibi consists of lipophilic cationic molecules. After being intravenously injected these molecules distribute throughout the body accordingly to the local blood supply and by passive diffusion through cell’s membrane accumulate intracellularly into the mitochondria [18, 19]. Normally 99mTc-sestamibi distributes in parotid and submandibular salivary glands, thyroid gland, the heart and the liver, but not in normal parathyroid glands. Visualization of parathyroid adenomas and hyperplastic parathyroid glands depends on the presence of oxyphillic cells, which are rich of mitochondria. The cells of parathyroid adenomas have plenty of mitochondria , while the normal parathyroid cells do not . The highest rates of uptake of 99mTc-sestamibi are seen in the solitary adenomas of the parathyroid glands . Not only the amount of intracellular mitochondria is important but also the quantity of oxyphillic cells in the tumors. If the percentage of oxyphillic cells exceeded 25%, accumulation of 99mTc-sestamibi was observed in 78% of parathyroid adenomas. Also false negative results are possible if the oxyphillic cells do not content sufficient amount of mitochondria . Accumulation of 99mTc-sestamibi into the cells also can be influenced by their metabolic activity, the weight and the size of the tumor. This new radionuclide rapidly replaced 201Tl chloride because it showed better quality of the images and higher sensitivity for detecting abnormal parathyroid glands, with less radiation exposure .
99mTc-tetrofosmin another myocardial perfusion agent was also used for visualizing parathyroid glands in scintigraphy, but the data for its use so far are limited. 99mTc-tetrofosmin shows some similarities with 99mTc-sestamibi although the way of accumulation is different and it is retained mainly in the cytosol rather than in the mitochondria of the target cells. When used for parathyroid scintigraphy 99mTc-tetrofosmin shows slower washout from the thyroid gland, which makes it unsuitable for single-isotope dual-phase scintigraphy . Nevertheless its sensitivity increases when used in combination with SPECT. Several studies [26, 27] of the diagnostic value of 99mTc-tetrofosmin scintigraphy for topic localization of the hyperfunctioning parathyroid glands in patients with PHPT, showed that this method was useful for the clinical practice and that the accumulation of 99mTc-tetrofosmin depends on the weight of the tumor and the level of PTH.
4.1 Protocols for nuclear medicine examination of parathyroid glands
Generally three protocols are most widely used: single-phase dual-isotope subtraction, dual-phase single-isotope and combination of both .
In single-phase dual-isotope modality two types of radiopharmaceuticals with different organ uptake are used. One isotope (99mTc-sestamibi or 99mTc-tetrofosmin) with equal thyroid and parathyroid glands accumulation and another (123I or 99mTc-pertechnetate) with predominant uptake in the thyroid gland are applied consecutively. The obtained images are digitally subtracted and if there is a residual radionuclide accumulation on the subtracted images a hyperfunctioning parathyroid gland can be suspected . Disadvantages of this method are the use of two radionuclides, the necessity of full collaboration from the patient’s side to stay calm and motionless during the examination and the need of very precise positioning of the patient. In addition there is an increase possibility for the presence of artifacts on the subtracted images [29, 30].
The rationale of the single-isotope protocol is based upon the different washout periods of the radionuclide from the thyroid and parathyroid glands. In this method, after an injection of a single radionuclide, early (at 10–15 min) and late (at 1.5–3 h) images are obtained .
There are a very few studies directly comparing the results from single-isotope dual-phase modality with single-phase dual-isotope subtractional scintigraphy and the results are inconclusive [31, 32]. So far there is no clear confirmed advantages of one type over another.
4.1.1 Preparation of the patient
No preliminary preparation of the patients before performing single isotope dual-phase scintigraphy is necessary. In subtractional modality some preliminary conditions should be followed such as: discontinuation of Levothyroxine or Iodine containing drugs minimum 20 days before the examination. A case history of every patient about the duration of the disease, any concomitant diseases and medications, especially drugs that could possibly interfere with the calcium-phosphate homeostasis, and family history should be taken.
99mTc-sestamibi and 99mTc-tetrofosmin: they are applied intravenously from 740 to 1110 MBq (20–30 mCi).
99mTc-pertechnetate has a half-life of 6 h and possesses energy of 140 keV. It is used for visualization of the thyroid gland because it accumulates in a functioning thyroid cells. Intravenously 99mTc-pertechnetate is applied form 74–350 MBq (2–10 mCi).
4.2 Single-isotope dual-phase scintigraphy with 99mTc-sestamibi and 99mTc-tetrofosmin
4.2.1 Single-isotope dual-phase scintigraphy with 99mTc-sestamibi
99mTc-sestamibi accumulates in the thyroid and parathyroid glands, but the washout time from both glands differs, showing faster disappearing from the thyroid and retention in parathyroid cells. This allows successful visualization of pathologically changed parathyroid glands on the obtained later images—1.5–2 h after the injection of the radionuclide. This different retention time in both glands may be related to some down-regulation of the P-glycoprotein system in parathyroid adenomas, which delays washout of the nuclide . Just the opposite, in parathyroid hyperplasia these so-called multidrug-related resistance molecules can be upregulated and can cause faster washout of 99mTc-sestamibi and lead to false negative results [34, 35].
To avoid this disadvantage and to improve sensitivity and specificity, the use of single-isotope dual phase (early and late) scintigraphy, based upon the suggestion that 99mTc-sestamibi is washed out faster from the thyroid gland than from the hyperfunctioning parathyroid cells, is recommended . This single-isotope dual phase scintigraphy gained popularity due to its convenience. The fact that 99mTc-sestamibi can also be accumulated in solitary thyroid nodules diminishes the specificity of this procedure, especially in areas with higher incidence of nodular goiter [37, 38]. Some parathyroid adenomas also show rapid washout of 99mTc-sestamibi and make their visualization difficult by this procedure . This led to an introduction of a modified protocol for subtractional scintigraphy by adding a second radionuclide with a preferential accumulation in the thyroid tissue.
99mTc-sestamibi scintigraphy is generally regarded to be the most sensitive and specific imaging modality especially when it is combined with other imaging procedures. The combination of US examination with dual-isotope 99mTc pertechnetate/99mTc-sestamibi scintigraphy for preoperative localization of parathyroid adenomas leads to visualizing of the parathyroid adenomas in 95.2% of the cases (20 patients out of 21). Reaching such high diagnostic precision allows to minimize the extent of the surgical procedure and gives way to apply routinely and successfully minimally invasive parathyroidectomy only of the pathologically changed glands [40, 41].
Comparing different imaging methods,99mTc-sestamibi scintigraphy has higher sensitivity and specificity than US and CT in discovering adenomas of the parathyroid glands. With regards to the hyperplasia of the parathyroid glands 99mTc-sestamibi scintigraphy shows to be of less value [42, 43]. Hyperplastic parathyroid glands are visualized in 10–62.5% of the cases [44, 45]. In multiple endocrine neoplasia syndrome (MEN), where hyperplasia of the parathyroid glands is common, only 55% of the abnormal glands are seen on 99mTc-sestamibi scintigraphy [42, 46, 47]. 99mTc-sestamibi scintigraphy shows to be highly effective in discovering ectopic hyperfunctioning parathyroid glands, which in some studies, are observed in approximately 20% of the cases with PHPT and represent a diagnostic and therapeutic challenge . Visualizing small parathyroid adenomas represents a specific problem. One study showed, that in surgically removed adenomas weighted less than 0.5 g, preoperative US was negative, but 99mTc-sestamibi scintigraphy discovered adenomas in 87% of cases and the combination with SPECT increased sensitivity to 95% .
In patients with SHPT, seems to have a direct correlation between 99mTc-sestamibi uptake with the blood level of parathyroid hormone and the phase of the cells’ cycles . The lowest level of accumulation corresponds to G(0) phase and the highest to phase G(2) + S. No such correlation with the weight of the glands is found . The fixation of the radionuclide depends on the functional status of the tissues, i.e., increased accumulation accompanies the cells’ active growing phase or is directly connected to the state of autonomy of the parathyroid cells .
The reason why not all pathologically changed parathyroid glands accumulate radionuclide remains unclear. This may be due to the different degree of activity and proliferation of the cells of the parathyroid adenomas. It was suggested that there is a relationship between nuclide accumulation and the degree of autonomy of the cells of the adenoma, i.e., the loss of the suppressive effect of calcium upon the secretion of the parathyroid hormone. The cells of the parathyroid adenomas and these of the hyperplastic glands show higher threshold for calcium suppression or have no threshold at all in comparison with the normal parathyroid cells. Due to this fact, these cells secrete more PTH for any given blood calcium level, show higher metabolic rate and capability to accumulate more 99mTc-sestamibi. Hyperplastic parathyroid glands are to some extent with preserved functional regulation, respond to the normal suppressive stimuluses, have lower metabolic rate and accumulate less of the radionuclide.
Due to its higher affinity to the parathyroid adenomas, 99mTc-sestamibi scintigraphy was used in cases of relapse of the hyperparathyroidism after parathyroidectomy or after autotransplantation of parathyroid glands.
Nowadays, there are several imaging methods for discovering hyperplastic parathyroid glands. The results so far are inconclusive. The dual-phase 99mTc-sestamibi scintigraphy in preoperative localization of the hyperplastic parathyroid glands in patients with profound secondary hyperparathyroidism do not show high sensitivity, but is of help to discriminate between patients with nodular and diffuse hyperplasia .
The role of 99mTc-sestamibi scintigraphy in patients with end-stage renal disease and secondary hyperparathyroidism is still unclear. The uptake of 99mTc-sestamibi can be suppressed by the use of calcitriol in these patients. In one study  99mTc-sestamibi scintigraphy managed to visualize 1 or more (maximum 3) parathyroid glands in most, but not in all patients on hemodialysis with PHT levels above 600 pg/ml. Performing suppressive test with calcitriol (2 mg of calcitriol applied i.v. after each hemodialysis for two consecutive weeks) showed suppression of 99mTc-sestamibi uptake at least in one parathyroid gland in 57% of the cases and full suppression in all glands in 36%. The basal level of PHT or its lowering after this test showed to be of no predictive value for the suppression of 99mTc-sestamibi uptake in the parathyroid glands. Because of its lower sensitivity, the 99mTc-sestamibi scintigraphy was found to be of limited value in preoperative evaluation in uremic patients with secondary hyperparathyroidism, but its significance grew up in localizing hyperfunctioning glands left after the first operation .
Single-isotope dual phase 99mTc-sestamibi scintigraphy is easily performed, and needs only application of 99mTc-sestamibi. After injection of the radiopharmaceutical, early (10–15 min), and late planar (1,5–3 h) images are obtained (Figures 1 and 2).
In some cases, the obtained early and late images show no signs of abnormal accumulation of radionuclide, but when combined with SPECT, than adenomas located at the back of the thyroid gland become visible (Figure 3a and b).
So, the combination of a single-isotope dual-phase scintigraphy with 99mTc-sestamibi with SPECT can be of great help.
SPECT has gained more importance, because it gives three-dimensional images. There are accumulating data from the literature, that it improves sensitivity for discovering and localizing the hyperfunctioning parathyroid glands [54, 55]. The main reason for this is the improved contrast resolution of SPECT (Figure 4).
4.2.2 Single-isotope dual-phase scintigraphy with 99mTc-tetrofosmin
99mTc-tetrofosmin, another myocardial perfusion agent, is also used for parathyroid scintigraphy, but there are limited data in the literature for its use. Several studies [26, 27] assess the diagnostic value of 99mTc-tetrofosmin scintigraphy for topic localization of the hyperfunctioning parathyroid glands in patients with PHPT. They show that this method was useful for the clinical practice and that the accumulation of 99mTc-tetrofosmin depended on the weight of the tumor and the level of PTH. The early images (15th min) prove to be better than the late ones (120th min). 99mTc-tetrofosmin is washed out more slowly from the thyroid gland than 99mTc-sestamibi but both radionuclides give better results in comparison with 99mTc-pertechnetate/201Tl-substractional technique . 99mTc-tetrofosmin looks promising alternative of 99mTc-sestamibi with similar properties and capabilities of localizing parathyroid adenomas.
Dual-isotope substractional scintigraphy with 99mTc-tetrofosmin/99mTc-pertechnetate and SPECT represent highly sensitive method for localization of parathyroid adenomas and their combination can further improve the diagnostic precision . 99mTc-tetrofosmin, like 99mTc-sestamibi is not perfect for localization of hyperplastic parathyroid glands in patients with SHPT, because of its lower sensitivity . 99mTc-tetrofosmin has some similarities with 99mTc-sestamibi, but its mechanism of accumulation in the cells is different. In contrast with 99mTc-sestamibi, which accumulation depends on mitochondria’s membrane potential, retention of 99mTc-tetrofosmin depends mainly on cell’s membrane potential . 99mTc-tetrofosmin, shows slower wash out from the thyroid on the late planar images (120 min). This leads to the necessity to obtain additional later planar images—between 150 and 160 min. This slower wash out makes 99mTc-tetrofosmin to be unsuitable for performing single-isotope, dual-phase scintigraphy . To avoid misleading, because of prolonged retention of the radiopharmaceutical in the thyroid adenomas, an US examination should be performed, especially in iodine deficient areas .
Figure 5 is presented a single-isotope dual-phase scintigraphy with 99mTc-tetrofosmin, combined with SPECT in a patient with PHPT.
In 99mTc-tetrofosmin scintigraphy early images at 20th min show better quality than the later ones at 120th min (Figure 6a–c).
Late planar images (120 min)—negative scan.
In this case, early SPECT gives opportunity to visualize adenomas, which were not seen on the late planar images, which is probably due to the rapid wash out of the radiopharmaceutical from some adenomas, as well as to the small sizes of the adenomas. When combined with SPECT, dual-phase scintigraphy with 99mTc-tetrofosmin can detect adenomas with rapid wash out of the radiopharmaceuticals.
The single isotope dual-phase scintigraphy with 99mTc-sestamibi or 99mTc-tetrofosmin could miss parathyroid adenomas with rapid washout of the radionuclide. The combination with early SPECT improves sensitivity.
The single isotope dual-phase scintigraphy with 99mTc-tetrofosmin in patients with PHPT and SHPT is with less sensitivity and specificity, because of the poor quality of the obtained images and slower washout of the radionuclide from the thyroid gland.
SPECT combined with single-isotope scintigraphy and subtractional methods for visualization of hyperfunctioning parathyroid adenomas in patients with PHPT and SHPT is a reliable additional modality. It does not cause additional and unnecessary exposure of the patients to the gamma-rays and can increase sensitivity.
4.3 Dual-isotope subtractional scintigraphy with: 99mTc-pertehnetat/99mTc sestamibi or 99mTc-pertehnetat/99mTc-tetrofosmin
4.3.1 Dual-isotope subtractional scintigraphy with 99mTc-pertehnetat/99mTc sestamibi
The rationale that stands behind dual-isotope subtractional scintigraphy with 99mTc-pertehnetat/99mTc sestamibi, is that 99mTc-sestamibi accumulates in both, thyroid gland and hyperfunctioning parathyroid glands, while 99mTc-pertechnetate uptakes only in the thyroid. First thyroid specific radionuclide 99mTc-pertechnetate is injected and at 30th min images are obtained. Afterwards, while the patient is still under the detector, second radionuclide 99mTc sestamibi with dual accumulation is applied and a second set of images on the 20th min are obtained. Later images are subtracted digitally from the first set of images and if a focus of residual activity on the subtractional images is detected, a hyperfunctioning parathyroid gland is supposed. The combination with early SPECT can improve sensitivity (Figure 7a and b).
The subtraction could be of help, when the patients had undergone surgery of the thyroid, but some thyroid parenchyma is still present. This method is important in the presence of more than one abnormal parathyroid gland.
Dual-isotope subtractional scintigraphy with 99mTc-pertehnetat/99mTc sestamibi combined with SPECT in a 51 years old man with MEN-type 1 syndrome—pheochromocytoma, parathyroid adenoma and prolactinoma, who had previously undergone thyroid (subtotal thyroidectomy) and parathyroid (left upper parathyroid gland) surgery. Subtractional images (Figure 8a) and early SPECT images (Figure 8b) show two areas of intense uptake located below the remnants of the both thyroid lobes. SPECT images show that the lesion below the right thyroid lobe was located also adjacent to the back part of the right thyroid lobe.
In some cases, obtaining late images could also be of help. Combining dual-isotope, 99mTc-pertehnetat/99mTc sestamibi, subtractional scintigraphy with SPECT, and also recording late planar images on the 120th min (late phase) would improve sensitivity (Figures 9 and 10).
Dual isotope subtractional scintigraphy with 99mTc-pertehnetat/99mTc sestamibi or 99mTc-pertehnetat/99mTc-tetrofosmin allows visualization of abnormal parathyroid glands after subtraction is performed, even on the early obtained images. This helps to shorten the time of examination to 80–90 min and is of great use in the postsurgical follow up and when more than one abnormal gland is present.
Disadvantages of the subtractional scintigraphy with 99mTc-pertehnetat/99mTc sestamibi or 99mTc-pertehnetat/99mTc-tetrofosmin are: necessity of applying of two radionuclides, the need of very precise positioning of the patients in this dual phase method requiring full collaboration from patient’s side and the probability of the presence of artifacts in the obtained images.
4.4 Secondary hyperparathyroidism
Secondary hyperparathyroidism is characterized with hyperplasia of parathyroid glands, because it is caused by longstanding uncontrolled hypocalcemia, which leads to a profound overstimulation of a previously normal parathyroid glands. Over time this overstimulation causes hyperplasia and eventually adenomatous changes (tertiary hyperparathyroidism) of the parathyroid glands with PTH levels far more exceeding those observed in PHPT (Figure 11). Nevertheless, hyperplastic parathyroid glands usually show faster wash out of the radionuclides in comparison to solitary adenomas, which makes them more difficult to be visualized with scintigraphy (Figure 12). Negative scans, may be associated with the possible suppression of the accumulation of radiopharmaceuticals in the parathyroid cells as a result of the concomitant calcitriol intake. The use of calcium channel blockers may affect the uptake of 99mTc-sestamibi by parathyroid cells and reduce the sensitivity of the method. A study found that negative scans are twice as likely in patients taking calcium antagonists than those who do not take these medications (OR2, 88.95% CI, 1.03–8.10, p 0.045) . So, adding the poor general condition of the patients, pathologically changed parathyroid glands are more difficult to be localized in SHPT than in PHPT.
The visualization of abnormal parathyroid glands is difficult due to their variations in number and localization. Noninvasive parathyroid imaging studies include 99mTc-sestamibi scintigraphy, ultrasonography, computed tomography scanning, magnetic resonance imaging, and positron emission tomography. There is a general consensus that the most sensitive and specific imaging modality is the scintigraphy with 99mTc-sestamibi or 99mTc-tetrofosmin. 99mTc-sestamibi scintigraphy significantly increases the role of preoperative scintigraphy in patients with hyperparathyroidism and allows unilateral surgical approach with minimally invasive parathyroidectomy to be used. Generally three protocols with the use of two radiopharmaceuticals, 99mTc-sestamibi or 99mTc-tetrofosmin, are most widely applied: single-phase dual-isotope subtraction, dual-phase single-isotope and combination of both. Each one of them has specific advantages and disadvantages. While, single parathyroid adenomas are localized with greater precision, hyperfunctioning parathyroid hyperplastic cells represent a real challenge to the imaging modalities.
Several factors can influence the radionuclide uptake in pathologically changed parathyroid cells:
Total calcium levels—higher preoperative calcium levels are more frequently seen in patients with positive scans.
Parathyroid hormone levels.
A significant correlation between radiopharmaceutical uptake and preoperative levels of PTH is observed. As higher PTH is, as higher is the possibility for positive scans.
Vitamin D levels.
Patents with vitamin D deficiency are more likely to have positive scans.
Suboptimal levels of vitamin D, can stimulate the growth of the parathyroid adenomas independently from hypocalcemia and 1,25-dihydroxyvitamin D3 deficit can change the set-point of calcium suppressive effect upon PTH secretion .
The use of calcium-channel blockers can influence the uptake of the radiopharmaceutical in the parathyroid cells diminishing the sensitivity of the method.
Size—although considered to be very important, it is not the only determining factor.
Type of cells of the parathyroid adenoma—because oxyphilic cells contain more mitochondria, they uptake radionuclides to a larger extent.
P glycoprotein and MDR gene products.
Uptake of 99mТс-sestamibi and 99mТс-tetrofosmin in the cells of the parathyroid adenomas depends on the activity of the P glycoprotein coded by MDR gene, which is functioning as an ATP dependent efflux pump, protecting against accumulation of lipophilic cationic radiopharmaceuticals, including 99mТс-tetrofosmin . The expression of P glycoprotein in the parathyroid adenomas appears to be important factor determining radiopharmaceutical uptake. In one study 71% (10 out of 14) of adenomas with high P glycoprotein membrane activity have shown negative scans, 70% (45 out of 64) with negative P glycoprotein expression (р = 0.006) have shown positive scans .
Kearns AE, Thompson GB. Medical and surgical management of hyperparathyroidism. Mayo Clinic Proceedings. 2002; 77(1):87-91
Taniegra ED. Hyperparathyroidism. American Family Physician. 2004; 69(2):333-339
Ruda JM, Hollenbeak C, Stack BC Jr. A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003. Otolaryngology and Head and Neck Surgery. 2005; 132(3):359-372
Russell CF, Laird JD, Ferguson WR. Scan-directed unilateral cervical exploration for parathyroid adenoma: A legitimate approach? World Journal of Surgery. 1990; 14(3):406-409
Hansberger HR, Osborn AG, Ross J, Macdonald A. Thyroid gland and parathyroid glands. In: Diagnostic and Surgical Imaging Anatomy: Brain, Head and Neck, Spine. Amirsys: Salt Lake City, Utah. p. 2006
Dufour DR, Wilkerson SY. Factors related to parathyroid weight in normal persons. Archives of Pathology & Laboratory Medicine. 1983; 107(4):167-172
Phitayakorn R, McHenry CR. Incidence and location of ectopic abnormal parathyroid glands. American Journal of Surgery. 2006; 191(3):418-423
Pellitteri PK, Sofferman RA, Randolph GW. Surgical management of parathyroid disorders. In: Cummings CW, Haughey BH, Thomas JR, Harker LA, Flint PW, editors. Cummings Otolaryngology: Head and Neck Surgery. 4th ed. Philadelphia Pa: Mosby; 2005
DeLellis RA. Surgical pathology of the parathyroid glands. In: Randolph G, editor. Surgery of the Thyroid and Parathyroid Glands. St. Louis, MO: Elsevier; 2003. pp. 571-577
De Feo MI, Colagrande S, Biagini C, Tonarei A, Vaggelli L, et al. Parathyroid glands: Combination of (99m)Tc MIBI scintigraphy and US for demonstration of parathyroid glands and nodules. Radiology. 2000; 241(2):393-402
Waldorf JC, van Heerden JA, Gorman CA, Grant CS, Wahner HW. (75Se) Selenomethionine scanning for parathyroid localization should be abandoned. Mayo Clinic Proceedings. 1984; 59:534-537
Van Husen R, Kim LT. Accuracy of surgeon performed ultrasound in parathyroid localization. World Journal of Surgery. 2004:1122-1126
Mortenson ME, Evans DB Hunter GJ, et al. Parathyroid exploration in the reoperative neck: Improved preoperative localization with 4D-computer tomography. Journal of the American College of Surgeons. 2008; 206:888-895
Dugonjic S, Ajdinovic B, Cerovic S, Jankovic Z. Validity of dual tracer 99mTc-tetrofosmin and Tc-pertechnetate sultraction parathyroid scintigraphy in patients with primary and secondary hyperparathyroidism. Vojnosanitetski Pregled. 2009; 66(12):949-953
Krausz Y, Horne T, Wynchank S, Halevy A. Lateral neck imaging for spatial localization of parathyroid tissue. Nuclear Medicine and Biology. 1995; 22(3):394
Bergenfelz A, Tennvall J, Valdermarsson S, Lindblom P, Tibblin S. Sestamibi versus thallium subtraction scintigraphy in parathyroid localization: A prospective comparative study in patients with predominantly mild primary hyperparathyroidism. Surgery. 1997; 121(6):601-605
Coakley AJ, Kettle AG, Wells CP, O’Doherty MJ, Collins RE. 99mTc-sestamibi—A new agent for parathyroid imaging. Nuclear Medicine Communications. 1989; 10(11):791-794
Weber CJ, Vansant J, Alazraki N. Value of technetium 99m sestamibi/iodine 123 imaging in reoperative parathyroid surgery. Surgery. 1993; 114(6):1011-1018
Bhatnagar A, Vezza PR, Bryan JA, Atkins FB, Ziessman HA. Technetium 99m sestamibi parathyroid scintigraphy: Effect of P-glycoprotein, histology and tumor size on detectability. Journal of Nuclear Medicine. 1998; 39:1617-1620
Chudzinski W, Niderla J, Lasiecka Z, Wilczynski G, Gornicka B, Wasiutynshi A, et al. P-glycoprotein expression influences the result of 99mTc-MIBI scintigraphy in tertiary hyperparathyroidism. International Journal of Molecular Medicine. 2005; 16:215-219
Grzela T, Chudzinski W, Lazarczyk M, Niderla J, Dziunycz P, Milewski L, et al. Persisted/recurrent hyperparathyroidism associated with development of multi-drug resistance phenotype and proliferation of parathyroid transplants. International Journal of Molecular Medicine. 2004; 14:559-599
Taillefer R, Boucher Y, Potvin C, Lambert R. Detection and localization of parathyroid adenomas in patients with hyperparathyroidism using a single radionuclide imaging procedure with technetium-99m-sestamibi (double-phase study). Journal of Nuclear Medicine. 1992; 33(10):1801-1807
Grzela T, Chudzinski W, Lasiecka Z, Niderla J, Wilczynski G, Gornicka B, et al. The calcium-sensing receptor and vitamin D receptor expression in tertiary hyperparathyroidism. International Journal of Molecular Medicine. 2006; 17:1801-1807
Casara D, Rubello D, Piotto A, Pelizzo MR. 99mTc-MIBI radio-guided minimally invasive parathyroid surgery planned on the basis of a preoperative combined 99mTc-pertechnetate/99mTc-MiBi and altrasound imaging protocol. European Journal of Nuclear Medicine. 2000; 27:1300-1304
Froberg AC, Valkema R, Bonjer HJ, Krenning EP. 99mTc-tetrofosmin or 99mTc sestamibi for double-phase parathyroid scintigraphy? European Journal of Nuclear Medicine and Molecular Imaging. 2003; 30:193-196
Hiromatsu Y, Ishibashi M, Nishida H, Okuda S, Miyake I. Technetium-99m tetrofosmin parathyroid imaging in patients with primary hyperparathyroidism. Internal Medicine. 2000; 39(2):101-106
Vallejos V, Martin-Comin J, Gonzalez MT, Rafecas R, Munoz A, Fernandez A, et al. The usefulness of Tc-99m tetrofosmin scintigraphy in the diagnosis and localization of hyperfunctioning parathyroid glands. Clinical Nuclear Medicine. 1999; 24(12):959-964
Palestro CJ, Tomas MB, Tronco GG. Radionuclide imaging of the parathyroid glands. Seminars in Nuclear Medicine. 2005; 35(4):266-276
Standrock D, Merino MJ, Norton JA, Neumann RD. Parathyroid imaging by Tc/Tl scintigraphy. European Journal of Nuclear Medicine. 1990; 16(8-10):607-613
Liehn JC, Delisle MJ, Flamen JB. Improvement of parathyroid Tl-Tc scintigraphy by using a new image subtraction method. European Journal of Nuclear Medicine. 1988; 14(4):184-189
Rauth JD, Sessions RB, Shupe SC, Ziessman HA. Comprasion of Tc-99m MIBI and Tl-201/Tc-99m pertechnetate for diagnosis of primary hyperparathyroidism. Clinical Nuclear Medicine. 1996; 21(8):602-608
Leslie WD, Dupont JO, Bybel B, Riese KT. Parathyroid 99mTc-sestamibi scintigraphy: Dual-traser subtraction in superior to double-phase washout. European Journal of Nuclear Medicine and Molecular Imaging. 2002; 29(12):1566-1570
As A, Koizumi K, Toyama K, Araki T. Uptake of technetium-99m-tetrofosmin, technetium-99m-MIBI and thallium-201 in tumor cell lines. Journal of Nuclear Medicine. 1996; 37(10):1551-1556
O’Donety MJ, Kettle AG, Wells CP, et al. Parathyroid imaging with technetium-99m-sestamibi:preoperative localization and tissue uptake studies. Journal of Nuclear Medicine. 1998; 33:313-318
Lee VS, Spritzer CE, Coleman RE, Wilkinson RHJ, Coogan AC, Leight GSJ. The complementary roles of fast spin-echo MR imaging and duble-phase 99m Tc-sestamibi scintigraphy for localization of hyperfunctioning parathyroid glans. American Journal of Roentgenology. 1996; 167(6):1555-1562
Moka D, Voth E, Dietlein M, et al. Technetium 99m-MIBI-SPECT: A higly sensitive diagnostic tool for localization of parathyroid adenomas. Surgery. 2000; 128(1):29-35
Casara D, Rubello D, Piotto D, Pelizzo MR. 99mTc-MIBI radio-guided minimally invasive parathyroid surgery planned on the basis of a preoperative combined 99mTc-pertechnetate/99mTc-MIBI and ultrasound imaging protocol. European Journal of Nuclear Medicine. 2000; 27(9):1300-1304
Melliere D, Hindie E, Voisin MC, et al. Primary hyperthyroidism. Optimization of surgical results with systematic preoperative 99mTc-sestamibi scintigraphy. Chirurgie. 1997; 122(2):98-104
Pons F, Torregrosa JV, Vidal-Sicart S, Sabater L, Fuster D, Fernandez-Cruz L, et al. Preoperative parathyroid gland localization with 99Tc-sestamibi in secondary hyperparathyroidism. European Journal of Nuclear Medicine. 1997; 24(12):1494-1498
Ishibashi M, Nishida H, Okuda S, Suekane S. Localization of parathyroid glands in hemodialysis patients using Tc-99m Sestamibi imaging. Nephron. 1998; 78:48
Walgenbach S, Dutkowski P, Andreas J, Bockisch A, Junginger T. 99mT-MIBI-scintigraphy before parathyroid surgery? Zentralblatt für Chirurgie. 2000; 124(3):214-219
Mimura Y, Kanauchi H, Ogawa T, Kammori M, Kaminishi M. Review of 41 patients operated on for primary hyperparathyroidism. Biomedicine & Pharmacotherapy. 2000; 54(Suppl. 1):72-76
Piga M, Bolasco P, Satta L, Altieri P, Loi G, Nicolosi A, et al. MariottiDouble phase parathyroid technetium-99m-MIBI scintigraphy to identify functional autonomy in secondary hyperparathyroidism. Journal of Nuclear Medicine. 1996; 37(4):565-569
Torregrosa JV. Usefulness of double-phase technetium-99m sestamibi scintigraphy in secondary hyperparathyroidism before parathyroidetomy. Journal of Nuclear Medicine. 1999; 40:1434-1440
Kusakabe K, Oshima M, Takami H, Murata H, Aburano T, Kabo A. Evaluation of clinical utility of 99mTc-MIBI scintigraphy in localization of hyperfunctioning parathyroid lesions in patients with hyperparathyroidism—A report of multicenter phase 3 clinical trials. Kaku Igaku. 1998; 35(9):887-899
Rothmund H, Diethelm J, Brunner C, et al. Diagnosis and surgical treatment of mediastinal parathyroid tumors. Annals of Surgery. 1976; 183:139-145
Rubello D, Mazzarollo R, Casara D. The role of technetium-99m sestamibi scintigraphy in the planning of therapy and follow-up of patient with differentiated thyroid carcinoma after surgery. European Journal of Nuclear Medicine. 2000; 27(4):431-440
Benard F, Lefebre B, Beuvon F, Langlois MF, Bisson G. Rapid washout of technetium-99-MIBI from a large parathyroid adenoma. Journal of Nuclear Medicine. 1995; 36(2):241-243
Hung GU, Wu HS, Tsai SC, Kao CH, et al. Recurrent hyperfunctioning in parathyroid gland demonstratedon radionuclide imaging and an intraoperative gamma probe. Clinical Nuclear Medicine. 2000; 25(5):348-350
Lomonte C, Buonvino N, Selvaggiolo M, Dassira M, Grasso G, Vernaglione L, et al. Sestamibi scintigraphy, topography, and histopathology of paratjyroid glands in secondary hyperparathyroidism. American Journal of Kidney Diseases. 2006; 48(4):638-644
Olaizola I, Zingrafe J, Heuguerot C, Fajardo L, Leger A, et al. 99mTc-Sestamibi parathyroid scintigraphy in chronic haemodialysis patients: Static and dynamic explorations. Nephrology, Dialysis, Transplantation. 2000; 15(8):1201-1206
Krausz Y, Horne T, Wynchank S, Halevy A. Lateral neec imaging for spatial localization of parathyroid tissue. Nuclear Medicine and Biology. 1995; 22(3):394
Arveschoug AK, Bertelsen H, Vammen B, Brochner-Mortensen J. Preoperative dual-phase parathyroid imaging with Tc-99m-sestamibi: Accuracy and reproducibility of pinhole collimator with and without oblique images. Clinical Nuclear Medicine. 2007; 32(1):9-12
Moka D, Voth E, Dietlein M, Larena-Avellaneda A, Schicha H. Technetium 99m-MIBI-SPECT: A highly sensitive diagnostic tool for localization of parathyroid adenomas. Surgery. 2000; 128(1):29-35
Lorberboym M, Minski I, Macadziob S, Nikolov G, Schachter P. Incremental diagnostic value of preoperative 99mTc-MIBI SPECT in patients with a parathyroid adenoma. Journal of Nuclear Medicine. 2003; 44(6):904-908
Gallowitsch HJ, Mikosch P, Kresnik E, Gomez I, Lind P. Technetium 99m tetrofosmin parathyroid imaging. Results with double-phase study and SPECT in primary and secondary hyperparathyroidism. Investigative Radiology. 1997; 32(8):459-465
Gallowitsch HJ, Mikosch P, Kresnik E, Unterweger O, Lind P. Comparison between 99mTc-tetrofosmin/pertechnetate subtraction scintigraphy and 99mTc-tetrofosmin SPECT for preoperative localization of parathyroid adenoma in an endemic goiter area. Investigative Radiology. 2000; 35(8):453-459
Friedman K, Somervell H, Patel P, Melton GB, Garrett-Mayer E, Dackiw AP, et al. Effect of calcium channel blockers on the sensitivity of pre-operative 99mTc-MIBI SPECT for hyperparathyroidism. Surgery. 2004; 136(6):1199-1204
Rao DS, Honasoge M, Divine GW, Phillips ER, Lee MW, Ansari MR, et al. Effect of vitamin D nutrition on parathyroid adenoma weight: Pathogenetic and clinical implications. The Journal of Clinical Endocrinology and Metabolism. 2000; 85(3):1054-1058
Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Research. 1993; 53(5):977-984
Gupta Y, Ahmed R, Happerfield L, Pinder SE, Balan KK, Wishart GC. P-glycoprotein expression is associated with sestamibi washout in primary hyperparathyroidism. The British Journal of Surgery. 2007; 94(12):1491-1495